DECEMBER 19 | VIRTUAL
Join STAT for our final event of 2023, coming up December 19th!
Cancer's Breakthrough Engine
In the two decades since Gleevec's development, precision cancer medicines have emerged as a pivotal force in biotech, giving patients hope as we see access to personalized treatment strategies increasing the chances for successful outcomes.
Join award-winning biotech reporter, Adam Feuerstein, for a discussion on the evolving landscape of these targeted treatments.
Adam will be joined by an expert panel (speaker announcements coming soon) to reflect on what has worked best, what hasn't, and the hottest new approaches in precision cancer medicines, including antibody drug conjugates, radiopharmaceuticals, tyrosine kinase inhibitors, and more.
REGISTER
No comments